NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis $32.89 +0.02 (+0.06%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$33.50 +0.61 (+1.85%) As of 09/11/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kodiak Sciences Stock (NASDAQ:KOD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kodiak Sciences alerts:Sign Up Key Stats Today's Range$32.31▼$34.0750-Day Range$32.87▼$45.4052-Week Range$8.91▼$47.84Volume682,562 shsAverage Volume564,651 shsMarket Capitalization$2.07 billionP/E RatioN/ADividend YieldN/APrice Target$48.14Consensus RatingModerate Buy Company Overview Kodiak Sciences Inc. (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration. Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration. Kodiak has also pursued KSI-501, a bispecific antibody biopolymer conjugate designed to target both VEGF and interleukin-6 pathways in retinal disease. Founded in 2009 and based in Palo Alto, California, Kodiak Sciences has focused primarily on research and clinical development rather than commercialized products. The company was founded and led by Victor H. Perlroth, who has served as its chief executive officer and a member of its board. Its clinical development activities have primarily addressed global ophthalmology markets through clinical trials and collaborations.AI Generated. May Contain Errors. Read More Kodiak Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreKOD MarketRank™: Kodiak Sciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 651st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingKodiak Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKodiak Sciences has a consensus price target of $48.14, representing about 46.4% upside from its current price of $32.89.Amount of Analyst CoverageKodiak Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Kodiak Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.89) to ($4.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 11.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kodiak Sciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.85% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 18.45, which indicates bearish sentiment.Change versus previous monthShort interest in Kodiak Sciences has recently increased by 4.63%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.44 News SentimentKodiak Sciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kodiak Sciences this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders44.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KOD Stock News HeadlinesKodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial VerdictsSeptember 3, 2026 | insidermonkey.comKodiak Sciences Advances ALTO Phase 3 Trial In Diabetic Eye DiseaseAugust 21, 2026 | tipranks.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 12 at 1:00 AM | Paradigm Press (Ad)Analysts Are Bullish on These Healthcare Stocks: Kodiak Sciences (KOD), ProQR (PRQR)August 19, 2026 | theglobeandmail.comKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsAugust 13, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Kalaris Therapeutics (KLRS)August 13, 2026 | theglobeandmail.comKodiak Sciences Inc.: Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular EdemaAugust 11, 2026 | finanznachrichten.deKodiak Sciences Says First Patients Enrolled in Late-Stage Diabetic Eye Disease TrialAugust 10, 2026 | finance.yahoo.comSee More Headlines KOD Stock Analysis - Frequently Asked Questions How have KOD shares performed this year? Kodiak Sciences' stock was trading at $27.96 at the start of the year. Since then, KOD stock has increased by 17.6% and is now trading at $32.89. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.09. When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Top institutional investors of Kodiak Sciences include BlackRock Inc. (6.61%), Braidwell LP (2.84%), Jupiter Topco LLC (2.44%) and California State Teachers Retirement System (2.13%). Insiders that own company stock include Bros Advisors Lp Baker and John A Borgeson. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK). Company Calendar Last Earnings8/12/2026Today9/12/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KOD's financial health is in the Green zone, according to TradeSmith. KOD has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KOD CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees124Year Founded2009Price Target and Rating Average Price Target for Kodiak Sciences$48.14 High Price Target$80.00 Low Price Target$15.00 Potential Upside/Downside+46.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$229.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-273.23% Return on Assets-85.48% Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book11.07Miscellaneous Outstanding Shares62,849,000Free Float34,944,000Market Cap$2.07 billion OptionableOptionable Beta2.18 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KOD) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersMy ‘one day’ retirement secretTradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...TradeSmith | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | SponsoredI called NVDA at $6 - Here's what’s next…Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
